Endometrial histology in long-term users of the once-a-month injectable contraceptive Cyclofem.
This study evaluated endometrial histology in women using the once-a-month injectable contraceptive Cyclofem for one year or more. The study received IRB approval. Seventeen Cyclofem users accepted to be submitted to an endometrial biopsy. All the samples were collected with an endometrial suction curette (Z-Sampler, ZSI Gynecological Product, Chasworth, CA, USA) in an outpatient clinic, 27-33 days after the last injection. The material was fixed immediately in Bouin solution prior to wax embedding and screened as a routine histological examination by a senior pathologist. The pathologist did not know the bleeding status of each woman or the number of injections each woman had received before the biopsy. All women recorded bleeding and spotting for the last 60 days prior to the biopsy. The mean age of volunteers was 25.9 years (range 21-32) and the mean number of injections received was 24.8 (range 14-47). The results were: 4 out of 17 biopsies were found to be inadequate for diagnosis because they consisted of only blood and mucus. Two of these women were bleeding regularly and the other 2 had amenorrhea. Eight endometrial samples presented a proliferative pattern and, in this group, 3 women had amenorrhea and 5 were bleeding regularly. The other 5 biopsies were reported as secretory endometrium, and 4 of them showed pseudodecidual reaction compatible with the administration of progestin. All of these women were bleeding regularly. The results of the biopsies were not related to the number of injections received nor to the age of the women. In conclusion, long-term administration of the injectable contraceptive Cyclofem did not produce adverse alterations in the endometrium as hyperplasia.
Bahamondes
L
L
Department of Obstetrics and Gynecology, School of Medicine, Universidade Estadual de Campinas (UNICAMP), Brazil.
Maradiegue
E
E
Diaz
J
J
Trelles
J
J
Escanhoela
C
C
Petta
C
C
Arce
X E
XE
D000328:Adult; D001706:Biopsy; D003271:Contraceptive Agents, Female / Q000009:adverse effects*; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D004717:Endometrium / Q000473:pathology*; D004958:Estradiol / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000009:adverse effects*
D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D004958:Estradiol; C034528:CycloProvera; D017258:Medroxyprogesterone Acetate